Shore Capital Reiterates “Buy” Rating for hVIVO (LON:HVO)

hVIVO (LON:HVO)‘s stock had its “buy” rating reissued by equities researchers at Shore Capital in a note issued to investors on Thursday, Marketbeat reports. They currently have a GBX 25 price target on the stock. Shore Capital’s target price suggests a potential upside of 320.88% from the stock’s current price.

Separately, Peel Hunt restated an “add” rating and issued a GBX 10 price objective on shares of hVIVO in a report on Thursday, November 20th. Two analysts have rated the stock with a Buy rating, According to MarketBeat, hVIVO currently has a consensus rating of “Buy” and an average price target of GBX 17.50.

hVIVO Price Performance

HVO stock opened at GBX 5.94 on Thursday. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The firm has a market capitalization of £40.82 million, a P/E ratio of 7.71 and a beta of 0.97. hVIVO has a 12 month low of GBX 4.31 and a 12 month high of GBX 20. The firm has a 50 day moving average of GBX 5.98 and a 200-day moving average of GBX 7.66.

Insider Buying and Selling

In other news, insider Stephen Pinkerton purchased 520,000 shares of the stock in a transaction dated Monday, December 15th. The shares were purchased at an average cost of GBX 6 per share, with a total value of £31,200. Also, insider Yamin Mo’ Khan purchased 3,310,405 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was purchased at an average price of GBX 6 per share, for a total transaction of £198,624.30. 4.43% of the stock is owned by corporate insiders.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.